4.6 Article

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

期刊

LANCET GLOBAL HEALTH
卷 9, 期 2, 页码 E144-E160

出版社

ELSEVIER SCI LTD
DOI: 10.1016/S2214-109X(20)30489-7

关键词

-

资金

  1. Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award - German Federal Ministry of Education and Research
  2. NIHR [HTA 09/104/40]
  3. Moorfields Eye Charity
  4. British Council to Prevent Blindness
  5. Fight for Sight
  6. International Glaucoma Association
  7. NIH [R01 EY015130, R01 EY017011, EY014800]
  8. Research to Prevent Blindness (NY, USA)
  9. National Health and Medical Research Council (NHMRC)
  10. National Heart Foundation
  11. Massachusetts Eye and Ear Global Surgery Program
  12. Sight for Souls
  13. Research Management Centre, Xiamen University Malaysia [XMUMRF/2020-C6/ITCM/0004]
  14. Secretaria Nacional de Ciencia, Tecnologia e Innovacion (SENACYT), Panama
  15. Egyptian Fulbright Mission Program
  16. National Eye Institute of the NIH [R01EY031209]
  17. National Institutes of Health Research (NIHR) [HTA/09/104/40] Funding Source: National Institutes of Health Research (NIHR)

向作者/读者索取更多资源

The study assessed the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020, finding that there was no change in the global prevalence of avoidable blindness and vision impairment in adults aged 50 and older. Although the age-standardized prevalence of avoidable blindness decreased, avoidable moderate and severe vision impairment did not change.
Background Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error. Methods We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10 degrees visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older. Findings Global crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change -0.2% [95% UI -1.5 to 1.0]; 2019 prevalence 9.58 cases per 1000 people [9s% IU 8.51 to 10.8], 2010 prevalence 96.0 cases per 1000 people [86.0 to 107-0]). Age-standardised prevalence of avoidable blindness decreased by -15.4% [-16.8 to -14.3], while avoidable MSVI showed no change (0.5% [-0.8 to 1.6]). However, the number of cases increased for both avoidable blindness (10.8% [8.9 to 12.4]) and MSVI (31.5% [30.0 to 33.1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15.2 million cases [9% IU 12.7-18.0]), followed by glaucoma (3.6 million cases [2-8-4.4]), undercorrected refractive error (2.3 million cases [1.8-2.8]), age-related macular degeneration (1.8 million cases [1.3-2.4]), and diabetic retinopathy (0.86 million cases [0.59-1.23]). Leading causes of MSVI were undercorrected refractive error (86.1 million cases [74.2-101.0]) and cataract (78.8 million cases [67.2-91.4]). Interpretation Results suggest eye care services contributed to the observed reduction of age-standardised rates of avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据